查看購物車
  • Simplified Chinese
  • English
  • Japanese
抗癌藥物市場規模及預測 2021 - 2031、全球及地區佔有率、趨勢及成長機會分析報告涵蓋範圍：依治療類型、按適應症、按配銷通路及按地域
市場調查報告書
商品編碼
1804880

抗癌藥物市場規模及預測 2021 - 2031、全球及地區佔有率、趨勢及成長機會分析報告涵蓋範圍：依治療類型、按適應症、按配銷通路及按地域

Cancer Drugs Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Therapy Type, By Indications, By Distribution Channel, and Geography
出版日期: | 出版商: The Insight Partners | 英文 277 Pages | 訂單完成後即時交付

價格

預計到2031年，抗癌藥物市場規模將從2024年的2,259.6億美元增加至5,161.5億美元。預計2025-2031年期間，該市場的複合年成長率將達到12.6%。推動市場成長的主要因素包括乳癌和肺癌發生率的上升，以及腫瘤學研究投資的激增，這些因素正在推動抗癌藥物的推廣應用。此外，在預測期內，個人化醫療的偏好可能會提振市場。然而，高昂的治療費用是市場發展的限制因素之一。

日益加重的肺癌負擔是驅動抗癌藥物市場的重要因素，尤其是在 2023 年。肺癌仍然是全球最常見和最致命的癌症之一，約佔所有癌症死亡人數的 25%。根據美國癌症協會的數據，2023 年，美國估計有 238,000 例新診斷出肺癌病例，約有 127,000 人死於該疾病。近一半的病例是在遠處（轉移性）階段被診斷出來的，這種情況下五年存活率下降到 29%，這凸顯了對更有效治療方案的迫切需求。這項嚴峻的統計數據凸顯了對有效治療方案的迫切需求，並刺激了對創新療法的需求。雖然吸菸仍然是約 85% 病例的主要危險因素，但從不吸菸者的肺癌比例正在上升，主要原因是空氣污染，特別是在低於世衛組織空氣品質標準的地區。非吸菸者中發病率的不斷上升，凸顯了對腺癌和其他與吸菸無直接關係的亞型的更廣泛適用的治療方法的未滿足需求。

早期檢測和精準醫療的進步對於應對這一日益嚴峻的挑戰至關重要。開發標靶療法、免疫療法和聯合療法可以提高存活率和生活品質。 2023年，用於治療EGFR突變型非小細胞肺癌（NSCLC）的新藥Tagrisso（奧希替尼）的獲批，以及正在進行的新型免疫檢查點抑制劑臨床試驗，將持續重塑治療模式。免疫療法已顯示出良好的療效，Keytruda（派姆單抗）和Opdivo（納武單抗）等藥物透過利用人體免疫系統對抗癌症，顯著改善了患者的預後。因此，乳癌發生率的上升推動了全球抗癌藥物市場的成長。此外，民眾對癌症意識的提高預計將對該市場的發展做出積極貢獻。

比較公司分析根據產品組合（產品滿意度、產品特性和可用性）、近期市場發展（併購、新產品發布和增強、投資和融資、獎勵、協議、合作和夥伴關係、認可和擴展）以及地理位置對抗癌藥物市場進行評估和分類，有助於更好地決策和了解競爭格局。該報告深入探討了全球抗癌藥物市場主要供應商近期的重要發展和創新。主要市場參與者包括百時美施貴寶公司、艾伯維公司、強生公司、羅氏有限公司、輝瑞公司、阿斯特捷利康公司、默克公司、諾華公司、安斯泰來製藥公司和禮來公司。

根據治療類型，抗癌藥物市場分為化療、標靶治療、放射治療、荷爾蒙治療和其他治療類型。標靶治療在2024年佔據了抗癌藥物市場的最大佔有率。

根據適應症，市場分為血癌、肺癌、乳癌、大腸癌、攝護腺癌、胃癌、子宮頸癌、肝癌和肝內膽管癌、甲狀腺癌和其他適應症。 2024 年，乳癌藥物佔據抗癌藥物市場的最大佔有率，預計 2025 年至 2031 年期間的複合年成長率最高。乳癌是最常見的癌症之一，全球每年約有 230 萬新病例被診斷出來。它是女性中的第一大癌症，並且仍然是全球癌症相關死亡的主要原因。然而，乳癌研究和治療的重大進展大大提高了存活率，特別是在早期診斷中。標靶治療、免疫療法和個人化治療方案的不斷發展繼續改變乳癌的治療模式。

從配銷通路來看，抗癌藥物市場分為醫院藥局、零售藥局和線上商店。 2024年，醫院藥房佔據了抗癌藥物市場的最大佔有率，預計在2025-2031年期間將實現最高的複合年成長率。

在抗癌藥物市場中營運的公司採用各種有機和無機成長策略。有機成長策略主要包括產品發布和產品批准。市場上常見的無機成長策略包括收購、合作和夥伴關係。這些成長策略使市場參與者能夠拓展業務，增強地域影響力，並促進整體市場成長。此外，收購和夥伴關係有助於鞏固客戶群並擴展產品組合。以下列出了抗癌藥物市場主要參與者的一些重要進展。

2024 年，默克公司（在美國和加拿大以外稱為 MSD）和私營臨床階段生物技術公司 LaNova Medicines Ltd.（LaNova）宣布，默克公司已獲得獨家全球許可，開發、生產和商業化 LM-299，這是 LaNova 的一種新型研究性 PD-1/VEGF 雙特異性抗體。

2024年，中國國家藥品監督管理局受理了安斯泰來和輝瑞的補充生物製品許可申請，​​將enfortumab vedotin與KEYTRUDA（帕博利珠單抗）聯合用於晚期膀胱癌的一線治療。

2023年，輝瑞宣布成功完成對Seagen公司的收購。 Seagen是一家全球生技公司，致力於發現、開發和商業化變革性抗癌藥物。輝瑞以每股229美元現金的價格完成了對Seagen所有流通普通股的收購，企業總價值約430億美元。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力

第3章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 顯影基數：
    • 數據三角測量：
    • 國家級資料：
  • 假設和局限性

第4章：抗癌藥物市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表

第5章：抗癌藥物市場－關鍵市場動態

  • 抗癌藥物市場－關鍵市場動態
  • 市場促進因素
    • 乳癌和肺癌負擔日益加重
    • 腫瘤學研究投資激增
  • 市場限制
    • 治療費用高昂
  • 市場機會
    • 政府和私人組織的支持增加
  • 未來趨勢
    • 個人化醫療偏好
  • 促進因素和限制因素的影響：

第6章：抗癌藥物市場-全球市場分析

  • 2021-2031年抗癌藥物市場收入
  • 抗癌藥物市場預測分析

第7章：抗癌藥物市場分析－依治療類型

  • 化療
  • 標靶治療
  • 免疫療法
  • 荷爾蒙療法
  • 其他治療類型

第 8 章：抗癌藥物市場分析 - 按適應症

  • 血癌
  • 肺癌
  • 乳癌
  • 大腸直腸癌
  • 攝護腺癌
  • 胃癌
  • 子宮頸癌
  • 肝臟和肝內膽管癌
  • 甲狀腺癌
  • 其他適應症

第9章：抗癌藥物市場分析－按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路商店

第10章：抗癌藥物市場-地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 亞太地區其他地區
  • 中東和非洲
    • 土耳其
    • 海灣合作理事會國家
    • 南非
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 12 章：產業格局

  • 概述
  • 市場計劃
  • 夥伴關係與合作
  • 其他發展

第13章：公司簡介

  • Bristol-Myers Squibb Co
  • AbbVie Inc
  • Astellas Pharma Inc
  • Eli Lilly and Co
  • Novartis AG
  • Merck KGaA
  • AstraZeneca
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson

第 14 章：附錄

Product Code: TIPRE00040984

The cancer drugs market is projected to reach US$ 516.15 billion by 2031 from US$ 225.96 billion in 2024. The market is estimated to register a CAGR of 12.6% during 2025-2031. Major factors driving the market growth include a growing burden of breast and lung cancer, and surging investments in oncology research are propelling the adoption of cancer drugs. Further, the preference for personalized medicine will likely boost the market during the forecast period. However, the high cost of treatment is among the market deterrents.

The growing burden of lung cancer is a significant driver of the cancer drugs market, particularly in 2023. Lung cancer remains one of the most prevalent and deadly cancers globally, accounting for ~25% of all cancer deaths. According to the American Cancer Society, in 2023, an estimated 238,000 new cases of lung cancer were diagnosed in the US, and ~127,000 people died from the disease. Nearly half of the cases are diagnosed at distant (metastatic) stages, where survival drops to a 29% five-year survival, underscoring the critical demand for more effective therapeutic options. This grim statistic underscores the pressing need for effective treatment options and fuels the demand for innovative therapeutics. Although smoking remains the leading risk factor responsible for ~85% of cases, there is a rising share of lung cancer among never-smokers, driven primarily by air pollution, particularly in regions below WHO air quality standards. The increasing incidence among non-smokers accentuates the unmet need for more widely applicable treatments targeting adenocarcinoma and other subtypes not directly linked to tobacco exposure.

Advancements in early detection and precision medicine are pivotal in addressing this growing challenge. Developing targeted therapies, immunotherapies, and combination treatments improves survival rates and quality of life. In 2023, the approval of new drugs such as Tagrisso (osimertinib) for EGFR-mutant NSCLC and the ongoing clinical trials of novel immune checkpoint inhibitors continue to reshape the therapeutic landscape. Immunotherapy has shown promising results, with drugs such as Keytruda (pembrolizumab) and Opdivo (nivolumab) significantly improving patient outcomes by harnessing the body's immune system to fight cancer. Therefore, the increasing incidence of breast cancer drives the global cancer drugs market growth. Additionally, the rising awareness of cancer among the population is expected to contribute positively to the development of this market.

The comparative company analysis evaluates and categorizes the Cancer Drugs market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global cancer drugs market. The key market players are Bristol-Myers Squibb Co.; AbbVie Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd; Pfizer Inc.; AstraZeneca Plc; Merck KGaA; Novartis AG; Astellas Pharma Inc.; and Eli Lilly and Co.

Based on therapy types, the cancer drugs market is segmented into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapy types. The targeted therapy segment held the largest cancer drugs market share in 2024.

By indications, the market is segmented into blood cancer, lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile ducts cancer, thyroid cancer, and other indications. The breast cancer segment held the largest share of the cancer drugs market in 2024 and is anticipated to register the highest CAGR from 2025 to 2031. Breast cancer is one of the most prevalent forms of cancer, with an estimated 2.3 million new cases diagnosed globally each year. It is the leading cancer in women and remains a prime cause of cancer-related mortality worldwide. However, significant advancements in breast cancer research and treatment have dramatically improved survival rates, particularly in early-stage diagnoses. Ongoing developments in targeted therapies, immunotherapies, and personalized treatment regimens continue to transform the therapeutic landscape for breast cancer.

In terms of distribution channel, the cancer drugs market is segmented into hospital pharmacies, retail pharmacies, and online stores. The hospital pharmacies segment held the largest share of the cancer drugs market in 2024 and is anticipated to register the highest CAGR during 2025-2031.

Companies operating in the cancer drugs market adopt various organic and inorganic strategies. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses, enhance their geographic presence, and contribute to the overall market growth. Furthermore, acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the cancer drugs market are listed below.

In 2024, Merck, known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, announced that Merck had entered into an exclusive global license to develop, manufacture, and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova.

In 2024, China's National Medical Products Administration accepted Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer.

In 2023, Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc., a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for US$ 229 in cash per share, for a total enterprise value of approximately US$ 43 billion.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:
  • 3.3 Assumptions and Limitations

4. Cancer Drugs Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in Value Chain

5. Cancer Drugs Market - Key Market Dynamics

  • 5.1 Cancer Drugs Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Growing Burden of Breast and Lung Cancer
    • 5.2.2 Surging Investments in Oncology Research
  • 5.3 Market Restraints
    • 5.3.1 High Cost of Treatment
  • 5.4 Market Opportunities
    • 5.4.1 Increased Support from Government and Private Organizations
  • 5.5 Future Trends
    • 5.5.1 Preference for Personalized Medicine
  • 5.6 Impact of Drivers and Restraints:

6. Cancer Drugs Market - Global Market Analysis

  • 6.1 Cancer Drugs Market Revenue (US$ Million), 2021-2031
  • 6.2 Cancer Drugs Market Forecast Analysis

7. Cancer Drugs Market Analysis - by Therapy Types

  • 7.1 Chemotherapy
    • 7.1.1 Overview
    • 7.1.2 Chemotherapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Targeted Therapy
    • 7.2.1 Overview
    • 7.2.2 Targeted Therapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.3 Immunotherapy
    • 7.3.1 Overview
    • 7.3.2 Immunotherapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.4 Hormonal Therapy
    • 7.4.1 Overview
    • 7.4.2 Hormonal Therapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.5 Other Therapy Types
    • 7.5.1 Overview
    • 7.5.2 Other Therapy Types: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Cancer Drugs Market Analysis - by Indications

  • 8.1 Blood Cancer
    • 8.1.1 Overview
    • 8.1.2 Blood Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Lung Cancer
    • 8.2.1 Overview
    • 8.2.2 Lung Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.3 Breast Cancer
    • 8.3.1 Overview
    • 8.3.2 Breast Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.4 Colorectal Cancer
    • 8.4.1 Overview
    • 8.4.2 Colorectal Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.5 Prostate Cancer
    • 8.5.1 Overview
    • 8.5.2 Prostate Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.6 Stomach Cancer
    • 8.6.1 Overview
    • 8.6.2 Stomach Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.7 Cervical Cancer
    • 8.7.1 Overview
    • 8.7.2 Cervical Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.8 Liver and Intrahepatic Bile Ducts Cancer
    • 8.8.1 Overview
    • 8.8.2 Liver and Intrahepatic Bile Ducts Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.9 Thyroid Cancer
    • 8.9.1 Overview
    • 8.9.2 Thyroid Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.10 Other Indications
    • 8.10.1 Overview
    • 8.10.2 Other Indications: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Cancer Drugs Market Analysis - by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Overview
    • 9.1.2 Hospital Pharmacies: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.2 Retail Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Retail Pharmacies: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.3 Online Stores
    • 9.3.1 Overview
    • 9.3.2 Online Stores: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Cancer Drugs Market - Geographical Analysis

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 North America Cancer Drugs Market Overview
    • 10.2.2 North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    • 10.2.3 North America: Cancer Drugs Market Share - by Therapy Types
      • 10.2.3.1 North America: Cancer Drugs Market- Revenue and Forecast Analysis - by Therapy Types
    • 10.2.4 North America: Cancer Drugs Market Share - by Indications
      • 10.2.4.1 North America: Cancer Drugs Market- Revenue and Forecast Analysis - by Indications
    • 10.2.5 North America: Cancer Drugs Market Share - by Distribution Channel
      • 10.2.5.1 North America: Cancer Drugs Market- Revenue and Forecast Analysis - by Distribution Channel
    • 10.2.6 North America: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.2.6.1 North America: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.2.6.2 United States: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.2.6.2.1 United States: Cancer Drugs Market Share - by Therapy Types
        • 10.2.6.2.2 United States: Cancer Drugs Market Share - by Indications
        • 10.2.6.2.3 United States: Cancer Drugs Market Share - by Distribution Channel
      • 10.2.6.3 Canada: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.2.6.3.1 Canada: Cancer Drugs Market Share - by Therapy Types
        • 10.2.6.3.2 Canada: Cancer Drugs Market Share - by Indications
        • 10.2.6.3.3 Canada: Cancer Drugs Market Share - by Distribution Channel
      • 10.2.6.4 Mexico: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.2.6.4.1 Mexico: Cancer Drugs Market Share - by Therapy Types
        • 10.2.6.4.2 Mexico: Cancer Drugs Market Share - by Indications
        • 10.2.6.4.3 Mexico: Cancer Drugs Market Share - by Distribution Channel
  • 10.3 Europe
    • 10.3.1 Europe Cancer Drugs Market Overview
    • 10.3.2 Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    • 10.3.3 Europe: Cancer Drugs Market Share - by Therapy Types
      • 10.3.3.1 Europe: Cancer Drugs Market- Revenue and Forecast Analysis - by Therapy Types
    • 10.3.4 Europe: Cancer Drugs Market Share - by Indications
      • 10.3.4.1 Europe: Cancer Drugs Market- Revenue and Forecast Analysis - by Indications
    • 10.3.5 Europe: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.5.1 Europe: Cancer Drugs Market- Revenue and Forecast Analysis - by Distribution Channel
    • 10.3.6 Europe: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.3.6.1 Europe: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.3.6.2 Germany: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.2.1 Germany: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.2.2 Germany: Cancer Drugs Market Share - by Indications
        • 10.3.6.2.3 Germany: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.6.3 United Kingdom: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.3.1 United Kingdom: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.3.2 United Kingdom: Cancer Drugs Market Share - by Indications
        • 10.3.6.3.3 United Kingdom: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.6.4 France: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.4.1 France: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.4.2 France: Cancer Drugs Market Share - by Indications
        • 10.3.6.4.3 France: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.6.5 Italy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.5.1 Italy: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.5.2 Italy: Cancer Drugs Market Share - by Indications
        • 10.3.6.5.3 Italy: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.6.6 Spain: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.6.1 Spain: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.6.2 Spain: Cancer Drugs Market Share - by Indications
        • 10.3.6.6.3 Spain: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.6.7 Rest of Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.7.1 Rest of Europe: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.7.2 Rest of Europe: Cancer Drugs Market Share - by Indications
        • 10.3.6.7.3 Rest of Europe: Cancer Drugs Market Share - by Distribution Channel
  • 10.4 Asia Pacific
    • 10.4.1 Asia Pacific Cancer Drugs Market Overview
    • 10.4.2 Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    • 10.4.3 Asia Pacific: Cancer Drugs Market Share - by Therapy Types
      • 10.4.3.1 Asia Pacific: Cancer Drugs Market- Revenue and Forecast Analysis - by Therapy Types
    • 10.4.4 Asia Pacific: Cancer Drugs Market Share - by Indications
      • 10.4.4.1 Asia Pacific: Cancer Drugs Market- Revenue and Forecast Analysis - by Indications
    • 10.4.5 Asia Pacific: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.5.1 Asia Pacific: Cancer Drugs Market- Revenue and Forecast Analysis - by Distribution Channel
    • 10.4.6 Asia Pacific: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.4.6.1 Asia Pacific: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.4.6.2 China: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.2.1 China: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.2.2 China: Cancer Drugs Market Share - by Indications
        • 10.4.6.2.3 China: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.6.3 Japan: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.3.1 Japan: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.3.2 Japan: Cancer Drugs Market Share - by Indications
        • 10.4.6.3.3 Japan: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.6.4 India: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.4.1 India: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.4.2 India: Cancer Drugs Market Share - by Indications
        • 10.4.6.4.3 India: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.6.5 South Korea: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.5.1 South Korea: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.5.2 South Korea: Cancer Drugs Market Share - by Indications
        • 10.4.6.5.3 South Korea: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.6.6 Australia: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.6.1 Australia: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.6.2 Australia: Cancer Drugs Market Share - by Indications
        • 10.4.6.6.3 Australia: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.6.7 Rest of APAC: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.7.1 Rest of APAC: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.7.2 Rest of APAC: Cancer Drugs Market Share - by Indications
        • 10.4.6.7.3 Rest of APAC: Cancer Drugs Market Share - by Distribution Channel
  • 10.5 Middle East and Africa
    • 10.5.1 Middle East and Africa Cancer Drugs Market Overview
    • 10.5.2 Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    • 10.5.3 Middle East and Africa: Cancer Drugs Market Share - by Therapy Types
      • 10.5.3.1 Middle East and Africa: Cancer Drugs Market- Revenue and Forecast Analysis - by Therapy Types
    • 10.5.4 Middle East and Africa: Cancer Drugs Market Share - by Indications
      • 10.5.4.1 Middle East and Africa: Cancer Drugs Market- Revenue and Forecast Analysis - by Indications
    • 10.5.5 Middle East and Africa: Cancer Drugs Market Share - by Distribution Channel
      • 10.5.5.1 Middle East and Africa: Cancer Drugs Market- Revenue and Forecast Analysis - by Distribution Channel
    • 10.5.6 Middle East and Africa: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.5.6.1 Middle East and Africa: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.5.6.2 Turkey: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.5.6.2.1 Turkey: Cancer Drugs Market Share - by Therapy Types
        • 10.5.6.2.2 Turkey: Cancer Drugs Market Share - by Indications
        • 10.5.6.2.3 Turkey: Cancer Drugs Market Share - by Distribution Channel
      • 10.5.6.3 GCC Countries: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.5.6.3.1 GCC Countries: Cancer Drugs Market Share - by Therapy Types
        • 10.5.6.3.2 GCC Countries: Cancer Drugs Market Share - by Indications
        • 10.5.6.3.3 GCC Countries: Cancer Drugs Market Share - by Distribution Channel
      • 10.5.6.4 South Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.5.6.4.1 South Africa: Cancer Drugs Market Share - by Therapy Types
        • 10.5.6.4.2 South Africa: Cancer Drugs Market Share - by Indications
        • 10.5.6.4.3 South Africa: Cancer Drugs Market Share - by Distribution Channel
      • 10.5.6.5 Rest of Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.5.6.5.1 Rest of Middle East and Africa: Cancer Drugs Market Share - by Therapy Types
        • 10.5.6.5.2 Rest of Middle East and Africa: Cancer Drugs Market Share - by Indications
        • 10.5.6.5.3 Rest of Middle East and Africa: Cancer Drugs Market Share - by Distribution Channel
  • 10.6 South and Central America
    • 10.6.1 South and Central America Cancer Drugs Market Overview
    • 10.6.2 South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    • 10.6.3 South and Central America: Cancer Drugs Market Share - by Therapy Types
      • 10.6.3.1 South and Central America: Cancer Drugs Market- Revenue and Forecast Analysis - by Therapy Types
    • 10.6.4 South and Central America: Cancer Drugs Market Share - by Indications
      • 10.6.4.1 South and Central America: Cancer Drugs Market- Revenue and Forecast Analysis - by Indications
    • 10.6.5 South and Central America: Cancer Drugs Market Share - by Distribution Channel
      • 10.6.5.1 South and Central America: Cancer Drugs Market- Revenue and Forecast Analysis - by Distribution Channel
    • 10.6.6 South and Central America: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.6.6.1 South and Central America: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.6.6.2 Brazil: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.6.6.2.1 Brazil: Cancer Drugs Market Share - by Therapy Types
        • 10.6.6.2.2 Brazil: Cancer Drugs Market Share - by Indications
        • 10.6.6.2.3 Brazil: Cancer Drugs Market Share - by Distribution Channel
      • 10.6.6.3 Argentina: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.6.6.3.1 Argentina: Cancer Drugs Market Share - by Therapy Types
        • 10.6.6.3.2 Argentina: Cancer Drugs Market Share - by Indications
        • 10.6.6.3.3 Argentina: Cancer Drugs Market Share - by Distribution Channel
      • 10.6.6.4 Rest of South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.6.6.4.1 Rest of South and Central America: Cancer Drugs Market Share - by Therapy Types
        • 10.6.6.4.2 Rest of South and Central America: Cancer Drugs Market Share - by Indications
        • 10.6.6.4.3 Rest of South and Central America: Cancer Drugs Market Share - by Distribution Channel

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Market Initiative
  • 12.3 Partnerships and Collaborations
  • 12.4 Other Developments

13. Company Profiles

  • 13.1 Bristol-Myers Squibb Co
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 AbbVie Inc
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Astellas Pharma Inc
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Eli Lilly and Co
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Novartis AG
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Merck KGaA
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 AstraZeneca
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Pfizer Inc
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 F. Hoffmann-La Roche Ltd
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Johnson & Johnson
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About Us
  • 14.2 List of Abbreviations

List Of Tables

  • Table 1. Cancer Drugs Market Segmentation
  • Table 2. List of Vendors
  • Table 3. Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Table 4. Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 5. Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 6. Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 7. North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 8. North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 9. North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 10. North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 11. United States: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 12. United States: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 13. United States: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 14. Canada: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 15. Canada: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 16. Canada: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 17. Mexico: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 18. Mexico: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 19. Mexico: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 20. Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 21. Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 22. Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 23. Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 24. Germany: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 25. Germany: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 26. Germany: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 27. United Kingdom: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 28. United Kingdom: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 29. United Kingdom: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 30. France: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 31. France: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 32. France: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 33. Italy: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 34. Italy: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 35. Italy: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 36. Spain: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 37. Spain: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 38. Spain: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 39. Rest of Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 40. Rest of Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 41. Rest of Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 42. Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 43. Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 44. Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 45. Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 46. China: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 47. China: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 48. China: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 49. Japan: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 50. Japan: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 51. Japan: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 52. India: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 53. India: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 54. India: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 55. South Korea: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 56. South Korea: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 57. South Korea: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 58. Australia: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 59. Australia: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 60. Australia: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 61. Rest of APAC: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 62. Rest of APAC: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 63. Rest of APAC: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 64. Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 65. Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 66. Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 67. Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 68. Turkey: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 69. Turkey: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 70. Turkey: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 71. GCC Countries: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 72. GCC Countries: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 73. GCC Countries: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 74. South Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 75. South Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 76. South Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 77. Rest of Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 78. Rest of Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 79. Rest of Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 80. South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 81. South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 82. South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 83. South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 84. Brazil: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 85. Brazil: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 86. Brazil: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 87. Argentina: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 88. Argentina: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 89. Argentina: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 90. Rest of South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 91. Rest of South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 92. Rest of South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 93. List of Abbreviations

List Of Figures

  • Figure 1. Cancer Drugs Market Segmentation - Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Cancer Drugs Market Revenue (US$ Million), 2021-2031
  • Figure 5. Cancer Drugs Market Share (%) - by Therapy Types (2024 and 2031)
  • Figure 6. Chemotherapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 7. Targeted Therapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. Immunotherapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 9. Hormonal Therapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 10. Other Therapy Types: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Cancer Drugs Market Share (%) - by Indications (2024 and 2031)
  • Figure 12. Blood Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. Lung Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 14. Breast Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Colorectal Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Prostate Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 17. Stomach Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. Cervical Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 19. Liver and Intrahepatic Bile Ducts Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 20. Thyroid Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 21. Other Indications: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. Cancer Drugs Market Share (%) - by Distribution Channel (2024 and 2031)
  • Figure 23. Hospital Pharmacies: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 24. Retail Pharmacies: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 25. Online Stores: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 26. Cancer Drugs Market Regional Share, 2024 and 2031 (%)
  • Figure 27. North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Figure 28. North America: Cancer Drugs Market Share - by Therapy Types (2024 and 2031)
  • Figure 29. North America: Cancer Drugs Market Share - by Indications (2024 and 2031)
  • Figure 30. North America: Cancer Drugs Market Share - by Distribution Channel (2024 and 2031)
  • Figure 31. North America: Cancer Drugs Market Share - Key Countries, 2024 and 2031 (%)
  • Figure 32. United States: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 33. Canada: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 34. Mexico: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 35. Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Figure 36. Europe: Cancer Drugs Market Share - by Therapy Types (2024 and 2031)
  • Figure 37. Europe: Cancer Drugs Market Share - by Indications (2024 and 2031)
  • Figure 38. Europe: Cancer Drugs Market Share - by Distribution Channel (2024 and 2031)
  • Figure 39. Europe: Cancer Drugs Market Share - Key Countries, 2024 and 2031 (%)
  • Figure 40. Germany: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 41. United Kingdom: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 42. France: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 43. Italy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 44. Spain: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 45. Rest of Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 46. Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Figure 47. Asia Pacific: Cancer Drugs Market Share - by Therapy Types (2024 and 2031)
  • Figure 48. Asia Pacific: Cancer Drugs Market Share - by Indications (2024 and 2031)
  • Figure 49. Asia Pacific: Cancer Drugs Market Share - by Distribution Channel (2024 and 2031)
  • Figure 50. Asia Pacific: Cancer Drugs Market Share - Key Countries, 2024 and 2031 (%)
  • Figure 51. China: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 52. Japan: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 53. India: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 54. South Korea: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 55. Australia: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 56. Rest of APAC: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 57. Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Figure 58. Middle East and Africa: Cancer Drugs Market Share - by Therapy Types (2024 and 2031)
  • Figure 59. Middle East and Africa: Cancer Drugs Market Share - by Indications (2024 and 2031)
  • Figure 60. Middle East and Africa: Cancer Drugs Market Share - by Distribution Channel (2024 and 2031)
  • Figure 61. Middle East and Africa: Cancer Drugs Market Share - Key Countries, 2024 and 2031 (%)
  • Figure 62. Turkey: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 63. GCC Countries: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 64. South Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 65. Rest of Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 66. South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Figure 67. South and Central America: Cancer Drugs Market Share - by Therapy Types (2024 and 2031)
  • Figure 68. South and Central America: Cancer Drugs Market Share - by Indications (2024 and 2031)
  • Figure 69. South and Central America: Cancer Drugs Market Share - by Distribution Channel (2024 and 2031)
  • Figure 70. South and Central America: Cancer Drugs Market Share - Key Countries, 2024 and 2031 (%)
  • Figure 71. Brazil: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 72. Argentina: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 73. Rest of South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 74. Heat Map Analysis by Key Players
  • Figure 75. Company Positioning and Concentration